From: 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis
Factor
Hazard Ratio
95% Confidence interval
p-value
Cumulative cisplatin dose
0.92
0.65–1.29
0.641
Gender
1.10
0.74–1.65
0.617
Age at diagnosis
1.01
0.99–1.03
0.089
Hypopharyngeal localisation
0.88
0.56–1.37
0.582
Smoking history
2.25
1.13–4.47
0.02